Antares pharma inc.
Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …
Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.27 Oct, 2021, 11:30 ET. NEW YORK, Oct. 27, 2021 /PRNewswire/ -- The testosterone replacement therapy market size is expected to increase by USD 113.54 million from 2019 to 2024, registering a CAGR ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma's (NASDAQ:ATRS) stock up by 8.0% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...
Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, manufacturing, and …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...
Exhibit 99.1 . Halozyme Completes Antares Pharma Acquisition . SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”).. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at …
Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...References: 1. NOCDURNA prescribing information: Ferring Pharmaceuticals Inc. Please see Prescribing Information including important safety information and boxed warning. * Source: Bloomberg/Symphony Health Solutions 0 100 200 300 400 500 600 700 800 NOCDURNA® Monthly TRx* NRx RefillsNov 10, 2022 · XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1, 8.4 ). Oct 18, 2021 · Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ...
He concurrently serves as the Director of the Board of Swiss based subsidiaries of the US pharmaceutical company Antares Pharma Inc. (Nasdaq: ATRS). Further to these noteworthy contributions, he ...
Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Thu, Nov. 05, 2020 Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript
Becton, Dickinson and Company, Sanofi, Pfizer, Inc, Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical, Merck KgaA, GlaxoSmithKline plc, Ypsomed, SHL Medical, Gerresheimer AG, Midas Pharma GmbH, Aptar Pharma, Solteam Medical, …Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022.Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Drug Delivery Devices market - The market share is expected to increase by USD 77.26 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.28%. Dental Delivery Systems market - The market share has the potential to grow by USD 100.32 million during 2019-2023. The growth momentum will accelerate throughout ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...23. 5. 2022 ...Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc , the …
Dec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma, Inc. announced the appointment of Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the...Antares Pharma Inc. Temple University - Fox School of Business and Management Report this profile About A senior pharmaceutical executive with over 20 years experience in operations, finance ...Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified ...Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ...3 Antares Pharma, Inc., Ewing, New Jersey, USA. 4 Men's Health Center, Miriam Hospital, Providence, Rhode Island, USA. PMID: 34510812 PMCID: PMC9293229 DOI: 10.1111/andr.13108 Abstract Background: To improve symptoms associated with testosterone deficiency, many testosterone therapies are available that aim to restore …
13. 4. 2022 ... Antares Pharma to be acquired by Halozyme in $960M deal ... Robert Apple, CEO of Antares Pharma. ... Antares, which was originally founded in Exton, ...On December 12, 2018, the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”) increased the size of the Board to eight members and, upon the recommendation of the Governance and Nominating Committee of the Board, appointed Peter Greenleaf to the Board as a Class I Director. Mr. Greenleaf’s term will expire at the …
About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several …Antares Pharma, Inc. (Antares or 'the company') is a drug device company that develops and markets self-injection pharmaceutical products and technologies. The company develops these products with its partners and is designed to provide functional and commercial advantages, such as reduced side effects, improved safety and efficacy and enhanced ...Otrexup™ Methotrexate, Preservative Free 15 mg / 0.4 mL Injection Prefilled Auto-Injector 4 Devices Antares Pharma Inc 54436001504.About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products ... Oct 18, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. Address Medical Inquiries to: Antares Pharma, Inc. Medical Communications 100 Princeton South, Suite 300 Ewing, NJ 08628, 1-855-Otrexup (1-855-687-3987) Nonclinical Toxicology. No Information provided. Use In Specific Populations Pregnancy Risk Summary. Based on published reports and methotrexate’s …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …
Home :: Antares Pharma. As of May 24, 2022 Halozyme completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable …
Antares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …
Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral …Mar 3, 2022 · EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted ... 23. 5. 2022 ...Antares Pharma is a leading company in the development and commercialization of self-administered injectable products. Learn more about its innovative portfolio, pipeline and financial performance in this investor presentation from January 2022.ANTARES PHARMA ANNOUNCES APPOINTMENT OF . ROBERT F. APPLE AS SENIOR VICE PRESIDENT AND CHIEF . FINANCIAL OFFICER . EXTON, PA (February 9, 2006) Antares Pharma, Inc. (Amex: AIS) today announced the appointment of Robert F. Apple to the position of Senior Vice President and Chief Financial Officer. Mr. Apple will be …Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...25. 4. 2022 ... FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. (ATRS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Antares Pharma, Inc. | Nasdaq: ATRS ...Antares Pharma, Inc. (Nasdaq - ATRS) Under the terms of the agreement, Antares will be acquired by Halozyme Therapeutics, Inc. (“Halozyme”) (Nasdaq - HALO). Antares stockholders will receive ...EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study ...
Jan 26, 2016 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Dec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, …All products displayed on Tata 1mg are procured from verified and licensed pharmacies. Book lab tests. Book any lab tests and preventive health packages from ...Instagram:https://instagram. public storage reitsbest low mileage car insurancetop stocks for day tradinglist of cyclical stocks Track Antares Pharma Inc (ATRS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAntares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ... liberty oilfieldtd bank atm limit withdrawal Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USAAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... what is a goldback Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...About Antares. Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective medicines. With a goal of improving dosing, reducing side effects, and improving patient compliance and outcomes, our pursuit of innovative therapies strives to ...